CLSD Stock Overview
A biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Clearside Biomedical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.35 |
| 52 Week High | US$2.12 |
| 52 Week Low | US$0.65 |
| Beta | 2.36 |
| 1 Month Change | 6.30% |
| 3 Month Change | -2.88% |
| 1 Year Change | 17.39% |
| 3 Year Change | -53.29% |
| 5 Year Change | 29.81% |
| Change since IPO | -81.38% |
Recent News & Updates
Recent updates
Here's Why We're Watching Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation
Nov 06
We're Keeping An Eye On Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Rate
Jun 24Here's Why We're Not At All Concerned With Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation
Nov 12Analyst Forecasts Just Became More Bearish On Clearside Biomedical, Inc. (NASDAQ:CLSD)
Aug 11Clearside Biomedical Q2 2022 Earnings Preview
Aug 08Clearside Biomedical: A Pivotal 2022 Ahead
Apr 13Clearside's Safety Data In Wet AMD And Emphasis On SCS Microinjector Make It Great Speculative Play
Dec 22Clearside Biomedical (NASDAQ:CLSD) Is In A Strong Position To Grow Its Business
Sep 30Clearside's Value Proposition Is Far From Clear
Aug 07We Think Clearside Biomedical (NASDAQ:CLSD) Can Easily Afford To Drive Business Growth
Jun 17Clearside Biomedical climbs after positive results from early-stage wet AMD trial
Jun 15Clearside Biomedical resubmits eye treatment XIPERE NDA
May 03If You Had Bought Clearside Biomedical (NASDAQ:CLSD) Shares A Year Ago You'd Have Earned 45% Returns
Feb 16Clearside Biomedical's early-stage wet AMD study gets underway
Jan 12Trade Alert: Bradford Whitmore At Clearside Biomedical, Inc. (NASDAQ:CLSD), Has Just Spent US$1m Buying 11% More Shares
Jan 12Clearside Bio drops 11% on launch of $12M direct offering
Jan 06Clearside Biomedical: SCS Microinjector Platform With Significant Upside
Jan 05Shareholder Returns
| CLSD | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -2.4% | -1.0% |
| 1Y | 17.4% | 16.7% | 25.2% |
Return vs Industry: CLSD exceeded the US Pharmaceuticals industry which returned 16.7% over the past year.
Return vs Market: CLSD underperformed the US Market which returned 25.2% over the past year.
Price Volatility
| CLSD volatility | |
|---|---|
| CLSD Average Weekly Movement | 14.0% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: CLSD's share price has been volatile over the past 3 months.
Volatility Over Time: CLSD's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 30 | George Lasezkay | clearsidebio.com |
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.
Clearside Biomedical, Inc. Fundamentals Summary
| CLSD fundamental statistics | |
|---|---|
| Market cap | US$103.24m |
| Earnings (TTM) | -US$34.97m |
| Revenue (TTM) | US$8.45m |
11.9x
P/S Ratio-2.9x
P/E RatioIs CLSD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CLSD income statement (TTM) | |
|---|---|
| Revenue | US$8.45m |
| Cost of Revenue | US$355.00k |
| Gross Profit | US$8.10m |
| Other Expenses | US$43.07m |
| Earnings | -US$34.97m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.47 |
| Gross Margin | 95.80% |
| Net Profit Margin | -413.72% |
| Debt/Equity Ratio | -203.5% |
How did CLSD perform over the long term?
See historical performance and comparison